newsfilter
← Latest News
Business Wire·

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma